CA2842518C - Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones - Google Patents
Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones Download PDFInfo
- Publication number
- CA2842518C CA2842518C CA2842518A CA2842518A CA2842518C CA 2842518 C CA2842518 C CA 2842518C CA 2842518 A CA2842518 A CA 2842518A CA 2842518 A CA2842518 A CA 2842518A CA 2842518 C CA2842518 C CA 2842518C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- salt
- mmol
- formula
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177119.2 | 2011-08-10 | ||
| EP11177119 | 2011-08-10 | ||
| PCT/EP2012/065733 WO2013021054A1 (en) | 2011-08-10 | 2012-08-10 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2842518A1 CA2842518A1 (en) | 2013-02-14 |
| CA2842518C true CA2842518C (en) | 2019-07-23 |
Family
ID=46650549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2842518A Active CA2842518C (en) | 2011-08-10 | 2012-08-10 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8906923B2 (2) |
| EP (1) | EP2742045B1 (2) |
| JP (2) | JP5921687B2 (2) |
| KR (1) | KR101996862B1 (2) |
| CN (2) | CN103874698B (2) |
| AR (1) | AR087508A1 (2) |
| AU (1) | AU2012293621B2 (2) |
| BR (1) | BR112014003063B1 (2) |
| CA (1) | CA2842518C (2) |
| CL (1) | CL2014000289A1 (2) |
| DK (1) | DK2742045T3 (2) |
| EA (1) | EA201490438A1 (2) |
| ES (1) | ES2721658T3 (2) |
| HU (1) | HUE042978T2 (2) |
| IL (1) | IL230549A (2) |
| JO (1) | JO3611B1 (2) |
| MX (1) | MX348128B (2) |
| PE (1) | PE20141410A1 (2) |
| PH (1) | PH12014500317A1 (2) |
| TR (1) | TR201905537T4 (2) |
| TW (1) | TWI568731B (2) |
| UA (1) | UA111210C2 (2) |
| UY (1) | UY34253A (2) |
| WO (1) | WO2013021054A1 (2) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| CN105503869A (zh) | 2011-08-10 | 2016-04-20 | 爱尔兰詹森科学公司 | 抗细菌的哌啶基取代的3,4-二氢-1h-[1,8]萘啶酮 |
| JP6250667B2 (ja) * | 2012-08-10 | 2017-12-20 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 新しい抗菌化合物 |
| AR097794A1 (es) | 2013-09-26 | 2016-04-13 | Mnemosyne Pharmaceuticals Inc | Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| US11691967B2 (en) | 2018-03-12 | 2023-07-04 | The Board Of Trustees Of The University Of Illinois | Antibiotics effective for gram-negative pathogens |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
| SMT202400519T1 (it) * | 2018-11-12 | 2025-01-14 | Debiopharm Int Sa | Composti antibiotici. metodi di produzione degli stessi, composizioni farmaceutiche contenenti gli stessi e loro usi |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| CN117440958A (zh) * | 2021-03-17 | 2024-01-23 | 爱尔兰詹森科学公司 | 抗菌化合物 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215123A (en) * | 1979-05-07 | 1980-07-29 | American Home Products Corporation | Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| WO2001026652A1 (en) | 1999-10-08 | 2001-04-19 | Smithkline Beecham Corporation | Fab i inhibitors |
| ATE294578T1 (de) | 1999-10-08 | 2005-05-15 | Affinium Pharm Inc | Fab i hemmer |
| HU230030B1 (hu) | 1999-10-08 | 2015-05-28 | Debiopharm International Sa | Fab I inhibitorok |
| EP1560584B1 (en) | 2001-04-06 | 2009-01-14 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| DK1828167T3 (da) | 2004-06-04 | 2014-10-20 | Debiopharm Int Sa | Acrylamidderivater som antibiotiske midler |
| US7732612B2 (en) | 2004-09-09 | 2010-06-08 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
| JP5468899B2 (ja) * | 2006-07-20 | 2014-04-09 | アフィニウム ファーマシューティカルズ， インク． | Ｆａｂｉインヒビターとしてのアクリルアミド誘導体 |
| EP2125802A4 (en) * | 2007-02-16 | 2014-08-20 | Debiopharm Int Sa | SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS |
| WO2011061214A1 (en) * | 2009-11-18 | 2011-05-26 | Fab Pharma Sas | Novel heterocyclic acrylamides and their use as pharmaceuticals |
| CA2843643A1 (en) | 2011-07-29 | 2013-02-07 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of hiv |
| US8766017B2 (en) | 2011-07-29 | 2014-07-01 | Eastman Chemical Company | Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid |
| CN105503869A (zh) | 2011-08-10 | 2016-04-20 | 爱尔兰詹森科学公司 | 抗细菌的哌啶基取代的3,4-二氢-1h-[1,8]萘啶酮 |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| US9394295B2 (en) | 2011-08-10 | 2016-07-19 | Janssen Sciences Ireland Uc | Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones |
-
2012
- 2012-08-07 JO JOP/2012/0223A patent/JO3611B1/ar active
- 2012-08-10 PE PE2014000186A patent/PE20141410A1/es active IP Right Grant
- 2012-08-10 US US14/237,862 patent/US8906923B2/en active Active
- 2012-08-10 CN CN201280038643.4A patent/CN103874698B/zh active Active
- 2012-08-10 ES ES12746093T patent/ES2721658T3/es active Active
- 2012-08-10 UY UY0001034253A patent/UY34253A/es active IP Right Grant
- 2012-08-10 EA EA201490438A patent/EA201490438A1/ru unknown
- 2012-08-10 CA CA2842518A patent/CA2842518C/en active Active
- 2012-08-10 DK DK12746093.9T patent/DK2742045T3/en active
- 2012-08-10 CN CN201511000870.XA patent/CN105461684B/zh active Active
- 2012-08-10 TW TW101128885A patent/TWI568731B/zh not_active IP Right Cessation
- 2012-08-10 PH PH1/2014/500317A patent/PH12014500317A1/en unknown
- 2012-08-10 AU AU2012293621A patent/AU2012293621B2/en not_active Ceased
- 2012-08-10 JP JP2014524410A patent/JP5921687B2/ja not_active Expired - Fee Related
- 2012-08-10 AR ARP120102929A patent/AR087508A1/es active IP Right Grant
- 2012-08-10 WO PCT/EP2012/065733 patent/WO2013021054A1/en not_active Ceased
- 2012-08-10 EP EP12746093.9A patent/EP2742045B1/en active Active
- 2012-08-10 MX MX2014001600A patent/MX348128B/es active IP Right Grant
- 2012-08-10 KR KR1020147005329A patent/KR101996862B1/ko not_active Expired - Fee Related
- 2012-08-10 BR BR112014003063-4A patent/BR112014003063B1/pt active IP Right Grant
- 2012-08-10 TR TR2019/05537T patent/TR201905537T4/tr unknown
- 2012-08-10 HU HUE12746093A patent/HUE042978T2/hu unknown
- 2012-10-08 UA UAA201400628A patent/UA111210C2/uk unknown
-
2014
- 2014-01-20 IL IL230549A patent/IL230549A/en active IP Right Grant
- 2014-02-05 CL CL2014000289A patent/CL2014000289A1/es unknown
- 2014-11-24 US US14/552,108 patent/US9290493B2/en active Active
-
2016
- 2016-03-16 US US15/071,612 patent/US9617262B2/en active Active
- 2016-04-12 JP JP2016079689A patent/JP2016190843A/ja not_active Withdrawn
-
2017
- 2017-03-09 US US15/454,703 patent/US9884864B2/en not_active Expired - Fee Related
- 2017-12-18 US US15/845,854 patent/US10155759B2/en active Active
-
2018
- 2018-11-16 US US16/194,052 patent/US10501463B2/en active Active
-
2019
- 2019-02-26 US US16/286,383 patent/US10526331B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2842518C (en) | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones | |
| CA2842531C (en) | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones | |
| CA2842526C (en) | Antibacterial homopiperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones | |
| CA2879623A1 (en) | Fused bicyclic azole heterocycle as inhibitors of the enzyme fabi | |
| CA2880262A1 (en) | Nitrogen-based heterocycloalkyl derivatives as inhibitors of the enzyme fabi | |
| HK1223352B (zh) | 抗菌的环戊二烯并[c]吡咯取代的3，4-二氢-1h-[1，8]萘啶酮 | |
| EA043636B1 (ru) | АНТИБАКТЕРИАЛЬНЫЕ 3,4-ДИГИДРО-1Н-[1,8]НАФТИРИДИНОНЫ, ЗАМЕЩЕННЫЕ ЦИКЛОПЕНТА[с]ПИРРОЛОМ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170809 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251014 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260325 |